Trials / Unknown
UnknownNCT04334265
Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019
Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 750 (estimated)
- Sponsor
- Peking University First Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of Anluohuaxian in blocking the progression of pulmonary fibrosis and improving lung function in patients with COVID-19.
Detailed description
In clinical institutions that enroll patients with corona virus disease 2019, two arms, multi-center, randomized and controlled methods are adopted. Patients are divided into two groups, Anluohuaxian combined with regular treatment group and regular treatment group. 750 patients are expected to be enrolled and the cases are allocated according to the ratio of 2( Anluohuaxian combined with regular treatment group): 1(regular treatment group).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anluohuaxian | 6g each time, twice a day |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2020-06-01
- Completion
- 2020-12-01
- First posted
- 2020-04-06
- Last updated
- 2020-04-24
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04334265. Inclusion in this directory is not an endorsement.